CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2015年 / 5卷 / 02期
关键词：
D O I：
10.1158/2159-8290.CD-RW2015-001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [31] The Effects of HER2 on CDK4/6 Activity in Breast Cancer
    Sinclair, William D.
    Cui, Xiaoyan
    CLINICAL BREAST CANCER, 2022, 22 (03) : E278 - E285
  • [32] CDK4/6 inhibitors in HER2-positive breast cancer
    Corona, Silvia Paola
    Ravelli, Andrea
    Cretella, Daniele
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Dester, Martina
    Gobbi, Angela
    Petronini, Pier Giorgio
    Generali, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 208 - 214
  • [33] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pretreated ER+/HER2- Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
  • [34] LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
    Xi Jin
    Li-Ping Ge
    Da-Qiang Li
    Zhi-Ming Shao
    Gen-Hong Di
    Xiao-En Xu
    Yi-Zhou Jiang
    Molecular Cancer, 19
  • [35] Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer
    Dan Moldoveanu
    Tanya L. Hoskin
    Courtney N. Day
    Amy K. Schulze
    Matthew P. Goetz
    Judy C. Boughey
    Breast Cancer Research and Treatment, 2024, 203 : 419 - 428
  • [36] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
  • [37] Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
    Petroni, Giulia
    Buque, Aitziber
    Yamazaki, Takahiro
    Bloy, Norma
    Di Liberto, Maurizio
    Chen-Kiang, Selina
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1855 - 1863
  • [38] Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HRD/HER2L metastatic breast cancer?
    Giordano, A.
    Lin, N. U.
    Tolaney, M.
    Mayer, L.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 10 - 14
  • [39] Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer
    Mazumder, Aloran
    Oropeza, Elena
    Punturi, Nindo
    Haricharan, Svasti
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
12345